ArticleInternational journal of molecular sciences2018
Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Pooled it
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.JAMA oncology · 2020Trial
- Efficacy and safety of immune checkpoint inhibitors in patients with high microsatellite instability/mismatch repair-deficient advanced cholangiocarcinoma: A propensity score-matched study.JHEP reports : innovation in hepatology · 2026Article
- Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.OncoTargets and therapy · 2026Review
- Immunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection.Frontiers in oncology · 2025Review
- Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.Cancer science · 2024Article
- Article
- Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma.Cancer biology & therapy · 2023Article
- Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.Cancers · 2023Review
- Precision Oncology Targets in Biliary Tract Cancer.Cancers · 2023Review
- Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.Targeted oncology · 2023Review
- Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.Frontiers in immunology · 2023Review
- Immunotherapy in Biliary Tract Cancers: Where Are We?Current oncology reports · 2022Review
- Targeted Therapies for Perihilar Cholangiocarcinoma.Cancers · 2022Review
- Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.Current oncology (Toronto, Ont.) · 2022Review
- Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review.Frontiers in pharmacology · 2022Article
- Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population.Oncology letters · 2022Article
- Primary small bowel adenocarcinoma with loss of nuclear expression of PMS2 after resection of mucinous cholangiocarcinoma.Journal of surgical case reports · 2022Article
- Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.Frontiers in medicine · 2022Review
- Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy.Exploration of targeted anti-tumor therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-modulating therapy is a promising therapy for patients with cholangiocarcinoma (CCA). Microsatellite instability (MSI) might be a favorable predictor for treatment response, but comprehensive data on the prevalence of MSI in CCA are missing. The aim of the current study was to determine the prevalence of MSI in a German tertiary care hospital. Formalin-fixed paraffin-embedded tissue samples, obtained in the study period from 2007 to 2015 from patients with CCA undergoing surgical resection with curative intention at Johann Wolfgang Goethe University hospital, were examined. All samples were investigated immunohistochemically for the presence of MSI (expression of MLH1, PMS2, MSH2, and MSH6) as well as by pentaplex polymerase chain reaction for five quasimonomorphic mononucleotide repeats (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.